Stock Ratings / Health Care / VALN / financials

ETRA (48) ENTX (40) SRZN (27) RGNX (39) ⌘ Pro Terminal →

Valneva SE (VALN) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$5.71 -0.52% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $5.69

Valneva SE (VALN) carries a Roarable Rating of D+ (Sell) with 58/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record: Scores of 58/100 (D+) historically posted market-perform odds over rolling 90-day windows (+0.0% avg 90D alpha vs SPY) →

ROARABLE D+ • SELL / AVOID Cap $541.8M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $5.69 (-0.28%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0.4% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 58/100 (D+) historically posted market-perform odds over rolling 90-day windows (+0.0% avg 90D alpha vs SPY • 52.7% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D+

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk B-

Each axis scored 0–20

12M PRICE TARGET CONE+0% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for VALN)Realized 20D OHLCV Swing Band: ±7.2%

Deterministic 5-Pillar Attribution (58/100 Composite)

🔍 WHY VALN SCORES 58/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+15/20 pts (26% of score)

FRED Regime × Technicals: 13% of 52W Range • RSI-14 at 42.1 (NEUTRAL RANGE)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (22% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution9/20 pts (-11 pt drag)

Disciplined Float (-0.40% YoY Shares) & executive Form 4 sales trim 11 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade B-$5.78-2.9% Next Q

Q2 (-2Q)

Grade C+$5.61-6.2% Next Q

Q3 (-1Q)

Grade C$5.26+8.6% Next Q

Current

Grade D+$5.71+0% Hist 90D α

Trajectory: B- (66) → D+ (58)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the VALN Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 58/100 (D+) score, VALN faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Company executives have done more routine share selling than personal cash buying lately.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Disciplined Float (-0.40% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($6.18) or 200D SMA ($6.82) invalidates the momentum regime and cuts Target Base ($5.71) toward Bear Floor ($4.45).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $VALN• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “VALN Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”

YES 58%NO 42%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • Trailing 12 Months

How VALN Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$15.2M (0.4% FCF Margin)

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring VALN)

✓Walkthrough of VALN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

VALN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +6.13%▲ ASCENDING CHANNEL

2026-10-30O $5.61H $5.71L $5.40C $5.71VOL 7.9K

RES: $7.85SUP: $5.29SMA50: $6.18SMA200: $6.82

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

VALN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 VALN Butterfly Map → + Track VALN →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on VALN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for VALN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for VALN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (VALN)

Health Care Rank #230 of 1016 ⚔️ ETRA vs VALN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (VALN vs. ETRA, ENTX, SRZN, RGNX)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Valneva SE (VALN) ranks #230 by composite RQD confidence (58/100, grade D+) and #435 by equity capitalization ($541.8M). Within this direct 5-issuer industry benchmark cohort, VALN leads on earnings valuation at N/A trailing P/E, while ENTX leads on capital efficiency and profitability with -33.6% ROIC and 0.0% gross margin. VALN currently leads its immediate peer cohort in composite quantitative strength at 58/100 (D+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
VALN ACTIVE Valneva SE	D+	58/100	—	—	—	-0.52%	$541.8M	Benchmark Subject
ETRA Electra Therapeutics Inc.	D	48/100	—	—	—	-3.79%	$542.3M	/etra-vs-valn →
ENTX Entera Bio Ltd.	D-	40/100	—	0.0%	-33.6%	+0.65%	$542.6M	/entx-vs-valn →
SRZN Surrozen Inc.	E	27/100	—	—	-35.0%	-2.93%	$524.4M	/srzn-vs-valn →
RGNX REGENXBIO Inc.	D-	39/100	—	—	-35.0%	+2.35%	$489.2M	/rgnx-vs-valn →

2. VALN Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Valneva SE (VALN) operates in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care) with an equity capitalization of $541.8M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. VALN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is VALN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Valneva SE (NASDAQ: VALN) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 58/100 at a spot price of $5.71 (-0.52% 1D, market cap $541.8M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, VALN ranks #230 in composite RQD confidence.

How does VALN compare to ETRA and ENTX in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), VALN carries a Roarable D+ (58/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, ETRA (Electra Therapeutics Inc.) holds a D grade (48/100 RQD, P/E N/A, ROIC —, cap $542.3M) and ENTX (Entera Bio Ltd.) posts a D- grade (40/100 RQD, P/E N/A, ROIC -33.6%, cap $542.6M). Among the 5-stock peer group, VALN leads on earnings multiple (N/A) while ENTX leads on capital efficiency (-33.6% ROIC).

What are the biggest fundamental strengths and SEC risk factors for VALN?

For Valneva SE (VALN), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #230 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.

Where is VALN trading relative to its 50-day, 200-day, and 52-week technical levels?

VALN last traded at $5.71 (-0.52% on volume of 11,519 shares), positioning the stock -7.61% below its 50-day simple moving average ($6.18) and -16.28% below its 200-day simple moving average ($6.82). Across its 52-week range of $4.75 to $12.18, VALN sits at the 12.9% percentile with a 14-day RSI of 42.1 (NEUTRAL RANGE) and an implied next-earnings move of ±7.2% ($5.30 to $6.12).

VALN Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is Valneva SE (VALN)?

In Trailing 12 Months, VALN converted $4.0B of revenue into a 52% gross margin, 27% operating margin, and $15.2M in free cash flow (0.4% FCF margin).

Direct Sub-Reports: VALN RQD Cockpit VALN 12M Forecast VALN Earnings & Move VALN Dividends & DRIP VALN Insiders & 13F VALN Whale Options VALN Profit Sankey VALN News & Why